More than five years after mRNA vaccines helped change the course of the COVID-19 pandemic, questions are emerging about what comes next for one of modern medicine’s most promising technologies. In a recent feature by The Scientist, WaNBRC Director Deborah H. Fuller, PhD, offers her perspective on the future of mRNA vaccine research, and why she believes its momentum will continue, even amid shifting political and funding priorities.
A pioneer in nucleic acid vaccine research, Fuller has worked in the field since the early days of DNA vaccine development in the 1990s. In the article, she discusses how decades of foundational science made the rapid development of COVID-19 mRNA vaccines possible and explains why the platform remains uniquely valuable for responding to emerging infectious diseases, seasonal threats like influenza, and even difficult targets such as HIV and fungal pathogens.
The article also explores recent federal decisions to reduce support for some mRNA vaccine initiatives, raising concerns among researchers about the long-term impact on U.S. scientific leadership and pandemic preparedness. Fuller acknowledges these challenges but remains optimistic. While reduced investment may slow progress in the United States, she emphasizes that mRNA technology is “here to stay” and that scientific discovery will continue advancing—whether in the U.S. or elsewhere.
“That magic is happening somewhere in the world,” Fuller told The Scientist. If the US chooses to not invest in mRNA research she said, “Our next vaccine against the next pandemic may not come from the scientists here. It may come from somewhere else.”
Her message is clear: mRNA vaccines represent far more than a pandemic-era success story. They are a transformative scientific platform with the potential to shape the future of global health for decades to come.
Read Director Fuller’s related work cautioning against cutting the funding last fall in this post.